Literature DB >> 2121699

Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae.

C E Cooper1, B Slocombe, A R White.   

Abstract

Concentrations of amoxycillin/clavulanic acid achievable in the respiratory tract following oral dosage were assessed for in-vitro activity against beta-lactamase-producing strains of Branhamella catarrhalis and Haemophilus influenzae. In agar-dilution studies, 8 mg amoxycillin/l was required to inhibit 45 strains of beta-lactamase-producing B. catarrhalis, whereas all the strains were inhibited by 0.5 mg amoxycillin/l in the presence of 0.01 mg clavulanic acid/l. Similarly, 0.1 mg amoxycillin plus 0.05 mg clavulanic acid/l were bactericidal against beta-lactamase-producing strain of B. catarrhalis and prevented regrowth within 24 h. In tests against 43 beta-lactamase-producing strains of H. influenzae, concentrations of up to 128 mg amoxycillin/l were required for inhibition, whereas 32 strains (75%) were fully sensitive to amoxycillin (MIC 0.5 mg/l) in the presence of 0.12 mg clavulanic acid/l. These concentrations of amoxycillin/clavulanic acid were also bactericidal for a beta-lactamase-producing strain of H. influenzae. The study therefore showed that amoxycillin/clavulanic acid, at concentrations similar to those likely to be achieved in the respiratory tract following oral dosage, was bactericidal in vitro for beta-lactamase-producing isolates of B.catarrhalis and H. influenzae.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121699     DOI: 10.1093/jac/26.3.371

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.

Authors:  Amparo Sánchez Navarro
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.

Authors:  Valerie Berry; Jennifer Hoover; Christine Singley; Gary Woodnutt
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Reduced-Concentration Clavulanate for Young Children with Acute Otitis Media.

Authors:  Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Jong-Hyeon Jeong; Diana H Kearney; Sonika Bhatnagar; Timothy R Shope; Gysella Muñiz; Judith M Martin; Marcia Kurs-Lasky; MaryAnn Haralam; Marcia A Pope; Jennifer P Nagg; Wenchen Zhao; Mohammad Kowser Miah; Jan Beumer; Raman Venkataramanan; Nader Shaikh
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 4.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

5.  Escherichia coli ATCC 35218 as a quality control isolate for susceptibility testing of Haemophilus influenzae with haemophilus test medium.

Authors:  D L Butler; C J Jakielaszek; L A Miller; J A Poupard
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

6.  Is the standard dose of amoxicillin-clavulanic acid sufficient?

Authors:  Michiel Haeseker; Thomas Havenith; Leo Stolk; Cees Neef; Cathrien Bruggeman; Annelies Verbon
Journal:  BMC Pharmacol Toxicol       Date:  2014-07-21       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.